Drug Trial Radar · NCT07801066
Testing Healthy Participants for Drowsiness After Single Dosing of Two Different Doses of Muscle Relaxer
Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
20
Planned (sponsor's estimate)
Start
Oct 15, 2026
Primary completion
Jan 15, 2027
Study completion Jan 15, 2027
Sponsor
- Lead sponsor
- Primus PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Sep 3, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Single (participant)
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Health participants take a single dose, perform testing, washout for one week, take a single dose of different formulation, and perform testing for comparison of the 2 doses.
Conditions
- Healthy Participants
Interventions
Metaxalone 640 mgDrug
Dose micronized 640 mg
Metaxalone 800 MGDrug
The dose is 800 mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline to approximately 4 hours post-dose, in mean reaction time to a stimulus as measured in milliseconds by the Reaction Time Test (RTT)Time frame: Baseline dose to four (4 ) hours post-dose
- Change from baseline to approximately 4 hours post-dose of delayed response exceeding a predefined threshold >300 ms as measured by the Reaction Time Test (RTT)Time frame: Baseline dose to approximately 4 hours post-dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
AMR Clinical - Columbus
Columbus, Ohio · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.